00:59 , Aug 4, 2018 |  BioCentury  |  Finance

Hong Kong’s first wave

Having broken the seal on the new biotech chapter of Hong Kong Exchange and Clearing Ltd., the performance of Ascletis Pharma Inc. and the next few companies to go out could determine what happens to...
15:31 , Jun 8, 2018 |  BC Week In Review  |  Financial News

Hua Medicine planning Hong Kong IPO

Diabetes company Hua Medicine Ltd. (Shanghai, China) filed for an IPO on the Hong Kong stock exchange underwritten by Goldman Sachs and CLSA Capital Markets. Hua is the second biotech company to file for a Hong...
15:20 , Jun 6, 2018 |  BC Extra  |  Financial News

Hua Medicine planning Hong Kong IPO

Diabetes company Hua Medicine Ltd. (Shanghai, China) filed for an IPO on the Hong Kong stock exchange underwritten by Goldman Sachs and CLSA Capital Markets. Hua is the second biotech company to file for a Hong...
18:05 , May 25, 2018 |  BioCentury  |  Finance

HKEX’s on-demand experts

The Hong Kong stock exchange is well aware its investor base is new to the high-risk, high-reward nature of its newly hatched biotech chapter and has no qualms about admitting its own lack of expertise....
17:20 , May 11, 2018 |  BC Week In Review  |  Clinical News

Hua's dorzagliatin reduces HbA1c in Phase II for Type II diabetes

Hua Medicine Ltd. (Shanghai, China) reported data from a double-blind, Chinese Phase II trial in 258 Type II diabetics showing that twice-daily 50 and 75 mg doses of oral dorzagliatin (sinogliatin, HMS5552, RO5305552) both significantly...
13:36 , Apr 13, 2018 |  BC Week In Review  |  Clinical News

vTv's azeliragon misses Alzheimer’s endpoint

vTv Therapeutics Inc. (NASDAQ:VTVT) said it will discontinue clinical trials of azeliragon (TTP488) after the Alzheimer’s disease candidate missed the co-primary endpoints in Part A of the Phase III STEADFAST trials to treat mild AD. STEADFAST...
23:11 , Apr 9, 2018 |  BC Extra  |  Clinical News

vTv's azeliragon misses Alzheimer’s endpoint

vTv Therapeutics Inc. (NASDAQ:VTVT) said it will discontinue clinical trials of azeliragon (TTP488) after the Alzheimer’s disease candidate missed the co-primary endpoints in Part A of the Phase III STEADFAST trials to treat mild AD....
15:17 , Mar 30, 2018 |  BC Week In Review  |  Financial News

Hua raises $117.4M with listing in sight

Hua Medicine Ltd. (Shanghai, China) raised a total of $117.4 million on March 27 in its series D and E rounds. New investors included Blue Pool Capital, GIC Private, AVICT Global, 6 Dimensions Capital, Adrian...
00:20 , Mar 30, 2018 |  BioCentury  |  Finance

Heading for Hong Kong

Raising substantially more than planned in a pair of oversubscribed venture rounds gives Hua Medicine Ltd. more breathing room as the Shanghai diabetes company readies itself to be among the first biotechs to list in...
16:23 , Mar 27, 2018 |  BC Extra  |  Financial News

Hua raises $117.4M with listing in sight

Hua Medicine Ltd. (Shanghai, China) raised a total of $117.4 million in its series D and E rounds. New investors included Blue Pool Capital, GIC Private, AVICT Global, 6 Dimensions Capital, Adrian Cheng via K11...